Overview

Study of PX-866 and Docetaxel in Solid Tumors

Status:
Completed

Trial end date:
2014-02-01

Target enrollment:

Participant gender:

Summary

Phase 1: To determine the maximally tolerated dose (MTD) or recommended dose (RD) and any potential efficacy of PX-866 in combination with docetaxel in patients with solid tumors. Phase 2: To determine the antitumor activity and safety of PX-866 in combination with docetaxel versus docetaxel alone in patients with NSCLC or SCCHN.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Cascadian Therapeutics Inc.

Treatments:

Docetaxel